10 assets in Myocardial Infarction

Therapeutic assets addressing Myocardial Infarction, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Aspirin Myocardial Infarction	Shanghai CureGene Pharmaceutical Co., Ltd.	P4	A (83)
Clopidogrel Myocardial Infarction	Shanghai CureGene Pharmaceutical Co., Ltd.	P4	A (81)
Ticagrelor Myocardial Infarction	Assistance Publique - Hôpitaux de Paris	P4	BBB (78)
Evolocumab Myocardial Infarction	Amgen	P4	B (63)
Cilostazol Myocardial Infarction	Stanford University	P3	B (60)
Colchicinum Myocardial Infarction	Assistance Publique - Hôpitaux de Paris	P3	B (60)
Dapagliflozin Myocardial Infarction	University of Sao Paulo	P2/3	B (57)
cg-0255 besylate Myocardial Infarction	Shanghai CureGene Pharmaceutical Co., Ltd.	P1	CC (43)
cg-0255 besylate for Myocardial Infarction	Shanghai CureGene Pharmaceutical Co., Ltd.	P1	CC (43)